



Press Release

STADA Executive Board shows satisfaction with financial year 2013 at Annual General Meeting and adheres to outlook for 2014

Bad Vilbel, June 4, 2014 – At the Annual General Meeting of STADA Arzneimittel AG, which took place today, on June 4, 2014, the Chairman of the Executive Board Hartmut Retzlaff showed satisfaction with financial year 2013 and adhered to the outlook for 2014.

In his speech, Retzlaff elaborated not only the challenges the Group was confronted with in the past financial year and the first quarter of 2014, but also the progress made within this period. He highlighted the further internationalization in the context of the active acquisitions policy as well as the expansion of the attractive-margin branded products segment. In addition, the Chairman of the Executive Board discussed the topics of personnel policy and personnel management, which play a very important role throughout the Group. Toward the end of his speech, Retzlaff summarized the opportunities and risks of the Group and confirmed the outlook for 2014 with a view to the strategic success factors. "In light of these strengths taken as a whole and our high-performing team, we continue to look to the future with optimism", summarized Retzlaff according to the manuscript of the speech.

The Annual General Meeting endorsed all of the Executive Board and Supervisory Board's proposals. And so a dividend of Euro 0.66 per STADA common share was resolved, which is significantly higher than the previous year by 32 percent, with the remaining surplus being carried forward. In addition, the Executive Board and the Supervisory Board were confirmed with a high level of approval. Furthermore, the Annual General Meeting confirmed the adjustment of existing control and profit transfer agreements of STADA Arzneimittel AG with some of its subsidiaries due to a change in legislation.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend



With the completion of STADA's Annual General Meeting today, there were – as a result of a regular new election in May of this year – changes in the employee representatives on the Supervisory Board. The new employee representatives on STADA's Supervisory Board are Dr. Ute Pantke, Halil Duru and Jens Steegers.

The wording of today's speech script of the Chairman of the Executive Board as well as the exact voting results for all items on the agenda can be found at STADA's website at www.stada.com/agm2014.

Additional information for analysts:

STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / e-mail: communications@stada.de

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-506 / e-mail: press@stada.de

Or visit us in the Internet at <http://www.stada.com>.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend